First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypo...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Format:	article
Langue:	EN RU
Publié:	Endocrinology Research Centre 2016
Sujets:	diabetes mellitus type 2 glycated hemoglobin нbа1с dpp-4 inhibitor gosogliptin vildagliptin Nutritional diseases. Deficiency diseases RC620-627
Accès en ligne:	https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Documents similaires